SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Public ClinicalTrials.gov record NCT03434262. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma
Study identification
- NCT ID
- NCT03434262
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Enrollment
- 68 participants
Conditions and interventions
Conditions
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Ganglioglioma
- Anaplastic Meningioma
- Anaplastic Oligodendroglioma
- Atypical Teratoid/Rhabdoid Tumor
- Brain Cancer
- Brain Tumor
- CNS Embryonal Tumor With Rhabdoid Features
- CNS Tumor
- Central Nervous System Neoplasms
- Choroid Plexus Carcinoma
- Embryonal Tumor With Multilayered Rosettes (ETMR)
- Embryonal Tumor of CNS
- Embryonal Tumor, NOS
- Ependymoma
- Ependymoma, NOS, WHO Grade II
- Ependymoma, NOS, WHO Grade III
- Ependymoma, RELA Fusion Positive
- Ependymoma, Recurrent
- Ganglioneuroblastoma of Central Nervous System
- Glioblastoma
- Glioblastoma, IDH-mutant
- Glioblastoma, IDH-wildtype
- Glioma
- Glioma, Diffuse Midline, H3K27M-mutant
- Glioma, High Grade
- Glioma, Malignant
- Glioma, Recurrent High Grade
- Glioma, Recurrent Malignant
- Medulloblastoma
- Medulloblastoma, Chromosome 9q Loss
- Medulloblastoma, G3/G4
- Medulloblastoma, Group 3
- Medulloblastoma, Group 4
- Medulloblastoma, Non-WNT Non-SHH, NOS
- Medulloblastoma, Non-WNT/Non-SHH
- Medulloblastoma, PTCH1 Mutation
- Medulloblastoma, SHH-activated and TP53 Mutant
- Medulloblastoma, SHH-activated and TP53 Wildtype
- Medulloblastoma, WNT-activated
- Medulloblastoma; Unspecified Site
- Medulloepithelioma
- Neoplasms
- Neoplasms, Neuroepithelial
- Neuroblastoma. CNS
- Neuroepithelial Tumor
- Neuroepithelial Tumor, High Grade
- Papillary Tumor of the Pineal Region (High-grade Only)
- Pediatric Brain Tumor
- Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)
- Pineoblastoma
- Pleomorphic Xanthoastrocytoma, Anaplastic
- Primitive Neuroectodermal Tumor
- Recurrent Medulloblastoma
- Refractory Brain Tumor
Interventions
- Gemcitabine Drug
- filgrastim Biological
- ribociclib Drug
- sonidegib Drug
- trametinib Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 1 Year to 39 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 4, 2018
- Primary completion
- Sep 29, 2022
- Completion
- May 23, 2024
- Last update posted
- May 30, 2024
2018 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03434262, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 30, 2024 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03434262 live on ClinicalTrials.gov.